Aileron Therapeutics
ALRN

$2.55

11.55%

Market Cap: 55.1M

About: Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.

Employees: 3

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

238% more capital invested

Capital invested by funds: $3.24M [Q4 2023] → $11M (+$7.71M) [Q1 2024]

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

15% more funds holding

Funds holding: 20 [Q4 2023] → 23 (+3) [Q1 2024]

12.78% more ownership

Funds ownership: 21.75% [Q4 2023] → 34.53% (+12.78%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target

$19

645%

upside

Avg. target

$19

645%

upside

High target

$19

645%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Ladenburg Thalmann

Aydin Huseynov

645%upside

$19

Buy

Maintained

18 Apr 2024

See Analyst Rankings

Financial journalist opinion

Aileron Therapeutics to be Included in the Russell Microcap® Index

AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization.

Aileron Therapeutics to be Included in the Russell Microcap® Index

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Zacks Investment Research

Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Aileron Therapeutics (ALRN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Aileron Therapeutics Announces CEO Transition

Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis diseases WALTHAM, Mass.

Aileron Therapeutics Announces CEO Transition

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

Topline results from Phase 1b study of LTI-03, Aileron's novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 Topline results from Phase 1b study of LTI-03, Aileron's novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

See News Rankings